Core Viewpoint - 康诺亚-B's CM512 has achieved all primary endpoints in its Phase I clinical trial for treating moderate to severe atopic dermatitis, indicating strong potential as a best-in-class treatment option [1] Company Summary - 康诺亚-B's stock rose by 3.14% to 64.25 HKD with a trading volume of 49.02 million HKD [1] - The company announced the successful completion of its Phase I clinical study for CM512, a long-acting TSLP x IL-13 dual blocker [1] - CM512 demonstrated rapid disease control, deep relief, and sustained efficacy with a half-life of 70 days and good safety profile [1] Industry Summary - CM512 is the world's first IgG-like long-acting TSLP x IL-13 dual blocker, targeting both TSLP and IL-13 to effectively treat type 2 inflammatory diseases [1] - The ongoing Phase II clinical studies for CM512 are focused on multiple indications, including atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria [1]
港股异动 | 康诺亚-B(02162)逆市涨超3% TSLP x IL-13双抗CM512特应性皮炎I期临床达成全部研究终点